Beneficial effect of serotonin 5-HT2-receptor antagonism on renal blood flow autoregulation in cyclosporin-treated rats

Journal of the American Society of Nephrology

Volumn 10, Issue 1, 1999, Pages 28-34

  Verbeke, Marleen ^a   Van De Voorde, Johan ^a   De Ridder, Leo ^a   Lameire, Norbert ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; RITANSERIN; SEROTONIN ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOREGULATION; CORRELATION FUNCTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; KIDNEY TUBULE PRESSURE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0032898452     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stier CT, McKendall G, Itskovitz HD: Serotonin formation in non blood-perfused rat kidneys. J Pharmacol Exp Ther 228: 53-56, 1984
2. Sole MJ, Madapalli Matam M, Baines AD: An active pathway for serotonin synthesis by renal proximal tubules. Kidney Int 29: 689-694, 1986
3. Van Neuten JM: Serotonin and the blood vessel wall. J Cardiovasc Pharmacol 7[Suppl 7]: S49-S51, 1985
4. Vanhoutte PM, Van Neuten JM, Janssens WJ: The role of the endothelium in the cardiovascular response to serotonin. In: Serotonin: From Cell Biology to Pharmacology and Therapeutics, edited by Paoletti R, Vanhoutte PM, Brunello N, Maggi FM, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1990, pp 81-96
5. Kopp J, Klotman PE: Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1: 162-179, 1990
6. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 7: 791-804, 1992
7. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 48[Suppl 52]: S70-S74, 1995
8. Bennett WM, DeMattros A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 50: 1089-1100, 1996
9. Kaskel FJ, Devarajan P, Arbeit LA, Moore LC: Effects of cyclosporine on renal hemodynamics and autoregulation in rats. Transplant Proc 20[Suppl 3]: 603-609, 1988
10. Verbeke M, Kesteloot D, Van de Voorde J, Lameire N, de Ridder L: Study of autoregulation of renal blood flow after endothelial NO-synthase inhibition or cyclosporin treatment in rats [Abstract]. Arch Int Pharmacodyn Ther 315: 126-127, 1992
11. Verpooten GA, Wybo I, Pattyn VM, Hendrix PG, Giulliano RA, Nouwen EJ, Roels F, De Broe ME: Cyclosporine nephrotoxicity: Comparative cytochemical study of rat kidney and human allograft biopsies. Clin Nephrol 25[Suppl 1]: 18-22, 1986
12. Brezis M, Epstein FH: Pathophysiology of acute renal failure. In: Toxicology of the Kidney, 2nd Ed., edited by Hook JB, Goldstein RS, New York, Raven Press, 1993, pp 129-152
13. Ueda D, Suzuki K, Malyszko J, Pietraszck MH, Takada Y, Takada A, Kawabe K: Fibrinolysis and serotonin under cyclosporine A treatment in renal transplant recipients. Thromb Res 76: 97-102, 1994b
14. Lau DCW, Wong KL, Hwang WS: Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int 35: 604-613, 1989
15. Moore LC, Mason J, Feld L, Van Liew JB, Kaskel J: Effect of cyclosporin A on endothelial albumin leakage in rats. J Am Soc Nephrol 3: 51-57, 1992
16. Diederich D Skopec J, Diederich A, Dai FX: Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 23: 957-961, 1994
17. 2+. Circ Res 74: 477-484, 1994
18. Berkenboom G, Brékine D, Fang ZY, Nève J, Fontaine J: Prevention by selenium supplementation of cyelosporin A induced vascular toxicity. Cardiovasc Res 33: 650-654, 1997
19. Neild GH, Reuben R, Hartley RB, Cameron JS: Glomerular thrombi in renal allografts associated with cyelosporin treatment. J Clin Pathol 37-8: 253-258, 1985
20. Kon V, Siguira M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 37: 1487-1491, 1990
21. Fernandes JB, Naik UR, Kornecki E: Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation. Cell Mol Biol Res 39: 265-274, 1993
22. Lameire N, Matthys E, Kesteloot D, Waterloos MA: Effect of a serotonin blocking agent on renal hemodynamics in the normal rat. Kidney Int 38: 823-839, 1990
23. Endlich K, Kühn R, Steinhausen M: Visualization of serotonin effects on renal vessels of rats. Kidney Int 43: 314-323, 1993
24. Verbeke M, Smöllich B, Van de Voorde J, de Ridder L, Lameire N: Beneficial influence of ketanserin on autoregulation of blood flow in post-ischemic kidneys. J Am Soc Nephrol 7: 621-627, 1996
25. Ueda D, Suzuki K, Malyszko J, Pietraszek MH, Takada Y, Takada A, Kawabe K: Serotonergic measures in cyclosporine A treated rats. Thromb Res 76: 171-179, 1994a
26. Darlametsos I, Morphake P, Bariety J, Hornych A, Tsipas G, Gkikas G, Papanikolaou N: Effects of ketanserin in cyclosporine-induced renal dysfunction in rats. Nephron 70: 249-254, 1995
27. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin CR, Mylecharane EJ, Saxena PR, Humphrey PPA: VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46: 157-203, 1994
28. Holstein-Rathlou NH, Marsh DJ: Renal blood flow regulation and arterial pressure fluctuations: A case study in nonlinear dynamics. Physiol Rev 74: 637-689, 1994
29. Arendshorst WJ, Finn WF, Gotschalck CW: Autoregulation of blood flow in the rat kidney. Am J Physiol 228: F127-F133, 1975
30. Kaskel FJ, Devarajan P, Birzgalis A, Moore LC: Inhibition of myogenic autoregulation in cyclosporine nephrotoxicity in the rat. Renal Physiol Biochem 12: 250-259, 1989
31. 2 antagonist. Drug Dev Res 15: 61-67, 1988
32. Mason J: Pharmacology of cyclosporine (Sandimmune) VII. Pathophysiology and toxicology of cyclosporin in humans and animals. Pharmacol Rev 42: 423-434, 1989
33. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 7: 791-804, 1992
34. Sturrock NDC, Struthers AT: Hormonal and other mechanisms involved in the pathogenesis of cyclosporin-induced nephrotoxicity and hypertension in man. Clin Sci 86: 1-9, 1994
35. Albornoz LE, Sanchez SB, Bandi JC, Canteros G, de las Heras M, Mastai RC: Pentoxyfylline reduces nephrotoxicity associated with cyclosporine in the rat by its rheological properties. Transplantation 64: 1404-1407, 1997
36. Verbeke M, Van de Voorde J, Lameire N: Functional study of cyclosporin-induced renal vasculotoxicity in rats. In: Proceedings of the 3rd International Satellite Symposium on ARF, edited by Papadimitriou M, Alexopoulos E, Halkidiki, Greece, 1993, pp 243-247
37. Verbeke M, Van de Voorde J, de Ridder L, Lameire N: Functional analysis of vascular dysfunction in cyclosporin-treated rats. Cardiovasc Res 28: 1152-1156, 1994
38. Bobadilla NA, Tapia E, Franco M, Lopez P, Mendoza S, Garcia-Torres R, Alvarado JA, Herrera-Acosta J: Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int 46: 773-779, 1994
39. Amore A, Gianoglio B, Ghigo D, Peruzzi L, Porcellini MG, Bussolino F, Costamagna C, Cacace G, Picciotto G, Mazzucco G, Sena LM, Coppo R: A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginine. Kidney Int 41: 1507-1515, 1995
40. Glennon RA: Central serotonin receptors as targets for drug research. J Med Chem 30: 1-12, 1987
41. Richardson BP, Hoyer D: Selective agonists and antagonists at 5-hydroxytryptamine receptor subtypes. In: Serotonin: From Cell Biology to Pharmacology and Therapeutics, edited by Paoletti R, Vanhoutte PM, Brunello N, Maggi FM, Dordrecht, The Netherlands, Kluwer Academic Publishers, 1990, pp 265-276